Read by QxMD icon Read

Journal of Comparative Effectiveness Research

Isabella Piassi Godói, Livia Lovato Pires Lemos, Vânia Eloisa de Araújo, Braúlio Cesar Bonoto, Brian Godman, Augusto Afonso Guerra Júnior
INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia(®)) was the first vaccine to gain regulatory approval to try and address this problem. AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. METHOD: Meta-analysis and systematic review. RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively...
January 13, 2017: Journal of Comparative Effectiveness Research
Jingyang Li, Zhenhua Wen, Anlie Cai, Feng Tian, Liang Zhang, Youwen Luo, Li Deng, Jingyun He, Yicheng Yang, Wendong Chen
AIM: To assess the cost-effectiveness of infliximab-containing therapy (ICT) for moderate-to-severe rheumatoid arthritis (RA) in a medium-sized Chinese city. METHODS: A Chinese prospective cohort study comparing ICT (25 patients) versus conventional disease-modified antirheumatic drugs (24 patients) for RA was used to assess the cost-effectiveness of ICT. RESULTS: The cohort study observed significantly reduced disease activity score of 28 joints (coefficient -2...
December 20, 2016: Journal of Comparative Effectiveness Research
Limor D Gonen
AIM: To measure the private and social benefits of donor insemination (DI). METHODS: An empirical model investigates the general public and DI clients' willingness to pay (WTP) for DI, and the willingness of potential donors to become altruistic or paid sperm donors. RESULTS: The general public and DI clients value DI and have a positive WTP for it, whereas willingness to donate, altruistically or for payment, is either low or very low. CONCLUSION: The general public's and DI clients' WTP for DI is in average above actual cost, so the government should consider funding or subsidizing DI...
November 17, 2016: Journal of Comparative Effectiveness Research
Laura Dormer
No abstract text is available yet for this article.
January 2017: Journal of Comparative Effectiveness Research
Adedunni Olusanya, Olayinka Ogunleye, Brian Godman, Joseph Fadare, Mustafa Danesi
AIM: Antiepileptic drugs do cause adverse effects, affecting patients' quality of life, adherence and seizures. Consequently, there is a need to study this among Nigerian patients. METHODS: Descriptive cross-sectional study assessing the extent of adverse effects with carbamazepine monotherapy and potential factors. RESULTS: 54 patients (64.3%) reported no adverse effects, while 30 did. The most common adverse effects were memory problems followed by headaches, restlessness, tiredness and depression...
January 2017: Journal of Comparative Effectiveness Research
Kara Contreary, Anna Collins, Eugene C Rich
We conduct a narrative literature review using four real-world cases of clinical decisions to show how barriers to the use of evidence-based medicine affect physician decision-making at the point of care, and where adjustments could be made in the healthcare system to address these barriers. Our four cases constitute decisions typical of the types physicians make on a regular basis: diagnostic testing, initial treatment and treatment monitoring. To shed light on opportunities to improve patient care while reducing costs, we focus on barriers that could be addressed through changes to policy and/or practice at a particular level of the healthcare system...
January 2017: Journal of Comparative Effectiveness Research
James H Flory, Jason Roy, Joshua J Gagne, Kevin Haynes, Lisa Herrinton, Christine Lu, Elisabetta Patorno, Azadeh Shoaibi, Marsha A Raebel
AIM: Laboratory test (lab) results may be useful to detect incident diabetes in electronic health record and claims-based studies. RESEARCH DESIGN & METHODS: Using the Mini-Sentinel distributed database, we assessed the value of lab results added to diagnosis codes and dispensing claims to identify incident diabetes. RESULTS: Inclusion of lab results increased the number of diabetes outcomes identified by 21%. In settings where capture of lab results was relatively complete, the absence of lab results was associated with implausibly low rates of the outcome...
January 2017: Journal of Comparative Effectiveness Research
Wei-Jhih Wang, Justin C Robertson, Anirban Basu
AIM: To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). METHODS: Associate the number of translational clinical trials in the USA involving oncolytic drugs approved during 2008-2013 and the level (in 2008) and changes (2002-2008 and 2008-2014) in cancer-specific years of life lost. RESULTS: Investments in trials were positively associated only with contemporary changes in BI (2008-2014)...
January 2017: Journal of Comparative Effectiveness Research
Mustafa Z Younis
Mustafa Z Younis speaks to Laura Dormer, Commissioning Editor: Dr Mustafa Z Younis is an internationally recognized scholar and was a member of the Executive Committee of the International Society for Research of Healthcare Financial Management. Dr Younis has authored and published over 200 articles, abstracts and presentations in refereed journals and meetings, and has presented at national and international conferences. Dr Younis has administrative experience as Senior Adviser for the President at Zirve University, Turkey and as Chair of the Department of Health Policy and Management at Florida International University (FL, USA) where he led the accreditation efforts for the Healthcare Management Program...
January 2017: Journal of Comparative Effectiveness Research
Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary
AIM: To conduct a systematic review investigating reasons for the disparity between the efficacy and effectiveness rates reported in randomized controlled trials (RCTs) and observational studies of direct-acting antiviral treatment regimens licensed for use in genotype1 hepatitis C virus-infected individuals. METHODS: This systematic review was conducted in accordance with the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses group...
January 2017: Journal of Comparative Effectiveness Research
Eugene C Rich
No abstract text is available yet for this article.
January 2017: Journal of Comparative Effectiveness Research
Richard White
No abstract text is available yet for this article.
January 2017: Journal of Comparative Effectiveness Research
Stephanie R Morain, Thomas W Concannon, Eve Wittenberg
Substantially engaging stakeholders in research involves making extensive changes to the full life cycle of research, from the initial stage of selecting research priorities to the final stages of dissemination and implementation. Recent scholarship has explored logistical and methodological challenges, including the time, training and resources required for engagement. However, inadequate attention has been given to the intended ends or goals of engagement - what do we want engagement to achieve? An examination of historical case studies can yield important insights regarding engagement and its intended ends...
January 2017: Journal of Comparative Effectiveness Research
Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Haliton Alves de Oliveira Junior, Adriana Maria Kakehasi, Augusto Afonso Guerra Junior, Marion Bennie, Brian Godman, Juliana Alvares
AIM: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. METHODS: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used...
November 2016: Journal of Comparative Effectiveness Research
Jonathan Alsop, Martin Scott, William Archey
Clinical trial designs often fail to deliver data that jointly satisfy evolving demands of both regulatory and reimbursement authorities. We propose a new multi-tiered trial design to integrate efficacy and effectiveness, and address the evolving needs of authorities. The mixed randomized trial allocates patients first to trial arm - randomized controlled, pragmatic (randomized) or observational - and then to treatment group - experimental, placebo, active comparator, best available therapy or standard of care...
November 2016: Journal of Comparative Effectiveness Research
Robert W Dubois
No abstract text is available yet for this article.
November 2016: Journal of Comparative Effectiveness Research
Mattias Neyt, Thierry Christiaens, Jacques Demotes, Tom Walley, Frank Hulstaert
AIM: Many questions of relevance to patients/society are not answered by industry-sponsored clinical trials. We consider whether there are benefits to governments in funding practice-oriented clinical trials. METHODOLOGY: A literature search including publications on institutions' websites was performed and supplemented with information gathered from (inter)national stakeholders. RESULTS: Areas were identified where public funding of clinical trials is of importance for society, such as head-to-head comparisons or medical areas where companies have no motivation to invest...
November 2016: Journal of Comparative Effectiveness Research
Roxanne E Jensen, Claire F Snyder, Ethan Basch, Lori Frank, Albert W Wu
In recent years, patient-reported outcomes have become increasingly collected and integrated into electronic health records. However, there are few cross-cutting recommendations and limited guidance available in this rapidly developing research area. Our goal is to report key findings from a 2013 Patient-Centered Outcomes Research Institute workshop on this topic and a summary of actions that followed from the workshop, and present resulting recommendations that address patient, clinical and research/quality improvement barriers to regular use...
November 2016: Journal of Comparative Effectiveness Research
Daniel E Jonas, Diego Garza
No abstract text is available yet for this article.
November 2016: Journal of Comparative Effectiveness Research
Nadeem Ahmed, Jaclyn Carberry, Vannesa Teng, David Carrick, Colin Berry
ST-elevation myocardial infarction (STEMI) is one of the leading causes of mortality and morbidity worldwide. While the survival after acute STEMI has considerably improved, mortality rate still remains high, especially in high-risk patients. Survival after acute STEMI is influenced by clinical characteristics such as age as well as the presence of comorbidities. However, during emergency care increasing access to tools such as the electrocardiogram, chest x-ray and echocardiography can provide additional information helping to further risk stratify patients...
November 2016: Journal of Comparative Effectiveness Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"